
Cabaletta Bio, Inc. Common Stock
CABA
CABA: Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
moreShow CABA Financials
Recent trades of CABA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CABA's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on CABA's company Twitter account
Number of mentions of CABA in WallStreetBets Daily Discussion
Recent insights relating to CABA
Recent picks made for CABA stock on CNBC
ETFs with the largest estimated holdings in CABA
Flights by private jets registered to CABA